Authors
Latest:
No More Excuses: It’s Time to Invest in the PharmacyOrganizations can go a long way toward ushering in the pharmacy of the future and enabling safer, more efficient care by implementing an intelligent infrastructure of technology.
Latest:
The IRA’s Impact on Patient Hub, Access, and Affordability ProgramsWhat does the legislation mean for patient access leaders, pharma brand managers, and patient service owners? Industry experts weigh in.
Latest:
Rethinking NCPs in support mixNon-commercial pharmacies can be secret weapons for intake and adherence
Latest:
The Opportunity for SustainabilityPharma’s prime chance to reduce carbon emissions from supply chain
Latest:
Achieving Efficient, Optimized, and Compliant Production at ScaleInnovation in pharma manufacturing as paradigms shift and biotech and personalized therapies move through clinical trials at pace
Latest:
Patient Data: Solving Ownership QuestionHow privacy and technology literacy can coexist behind a blockchain-based approach to patient data analytics and control
Latest:
How State Privacy Laws Are Shaping DTC and HCP Marketing StrategiesWhy they are a game changer, and ways to a adapt to a new era of state privacy regulations.
Latest:
Creating a Future-Ready Chemicals and Materials Lab Vital for GrowthTeams need to keep close track of ingredients, processing parameters, and material performance so that they can use their R&D data to decide exactly which materials to make next.
Latest:
FDA Gives Alzheimer’s Drug Leqembi Full Approval. That Means Medicare Coverage But...Medicare-eligible patients need to be enrolled in registry to get Medicare coverage for the anti-beta amyloid drug that is priced to cost $26,500 a year.
Latest:
Shipping Strategies in Unusual TimesThe steps pharma manufacturers can take to mitigate transportation costs amid Covid’s supply-chain crunch
Latest:
Expert: Digital Transformation is Key Part of Biopharma C-Suite Goals for 2024Stephanie L. Woerner, PhD, director and principal research scientist at the MIT Center for Information Systems Research, discusses the outlook for next year among biopharma firms.
Latest:
Unique Challenges to Market Access for Ophthalmology BiosimilarsCatherine Humphries sheds light on three key market access challenges within the ophthalmology biosimilars space.
Latest:
The Advantages of New Medicare Rx Payment PlanWhile the program could be a good option for many, it's not a panacea.
Latest:
Machine Health in Pharmaceutical ProductionPredictive maintenance in pharmaceutical production can help reduce downtime and increase efficiency. Grundfos Machine Health (GMH) uses artificial intelligence (AI)-driven wireless sensors to monitor motor health in real-time, identifying potential issues. This approach not only reduces maintenance costs but also ensures compliance with industry standards.
Latest:
Reshaped Priorities Pave Cold Chain PathHow recent advancements in practice and technology have ushered in a new era of pharmaceutical logistics.
Latest:
Right product, right place, right awayA prescription for making the pharma supply chain more resilient, reliable and disruption-proof
Latest:
Keeping Do-Not-Freeze Injectable Drugs Safe Through the Last MileAlongside the proper temperature-monitoring technology, optimal production control is necessary for success in cold chain drug delivery.
Latest:
11 Market Access Questions to Address Prior to Launching Your First Specialty DrugWednesday, October 5, 2022, 11am EDT Market access considerations can be complex to navigate and overwhelming to address for biopharmaceutical commercial teams launching their first specialty drug. Get answers to eleven key questions that will help guide commercial teams in effectively launching specialty products.
Latest:
The Consolidated Appropriations Act and PBM TransparencyNew federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.
Latest:
The Key Steps Ahead of DSCSA D-DayA recommended checklist for manufacturers as they enlist distributor and 3PL support—and the important questions they should be asking themselves
Latest:
The Burgeoning Specialty Drug Market: A Case for Guaranteed ValueAn actionable perspective on the future of specialty drug value-based contracting
Latest:
Plan of attack for small company supplier negotiationsHow emerging life sciences organizations can create value with suppliers
Latest:
Bridging the Divide: Understanding Contrasting Approaches in Drug DevelopmentAnalyzing the divergent paths undertaken by small biotech and large pharma companies in drug development.
Latest:
Preparing for Peak Season with Temperature-controlled ContainersThe pharma logistics peak season—and most of 2022—is going to be challenging for pharmaceutical shippers, forwarders and the air cargo industry. But making slight changes—such as choosing the right packaging—can make it easier.
Latest:
Navigating the Complexities of Prescription Drug Pricing: Affordable Solutions Are Available to Self-Insured Plan SponsorsThe lack of transparency in the pharmaceutical industry further exacerbates the challenges faced by consumers.
Latest:
The CGT Evolution: Key ConsiderationsHow cell and gene therapies can be safely protected as they move along the supply chain, even when temperature-related challenges present themselves.
Latest:
High-Tech Hubs and Specialty PharmaWith the rapid rise of the specialty drug market, manufacturers are increasingly relying on new advances used by patient hubs to boost their levels of patient engagement.
Latest:
In the Shadows of the Drug Affordability Debate, Patients Pay the Ultimate PriceAll healthcare stakeholders must participate to dismantle barriers and ensure access to medicines that save lives.
